The GLP-1 surge: What the real-world data reveals
Ozempic and Semaglutide drive a 587% spike in GLP-1 prescriptions Prescriptions for GLP-1 receptor...
Ozempic and Semaglutide drive a 587% spike in GLP-1 prescriptions Prescriptions for GLP-1 receptor...
Prostate cancer is the most common cancer among men, aside from skin cancer, and is known for being...
Traditional data aggregators are not enough The pharmaceutical industry is hitting a wall. Data...
Open claims and closed payer claims data are essential for understanding the status and activities...
Ozempic and Semaglutide drive a 587% spike in GLP-1 prescriptions Prescriptions for GLP-1 receptor agonists, including Ozempic, Semaglutide, and Rybelsus, have surged over the last five years as their effectiveness in promoting weight loss gains atte...